Table 1.
Baseline characteristics of IBD patients with COVID-19.
| Variable | IBD patients with COVID-19 [n = 100] | Missing values |
|---|---|---|
| Male sex, n [%] | 46 [46.0] | 0 |
| Comorbidities, n [%] | ||
| Any comorbidity | 59 [59.0] | 0 |
| Diabetes | 20 [20.0] | 0 |
| Hypertension | 33 [33.0] | 0 |
| Cardiovascular disease | 32 [32.7] | 2 |
| Asthma or chronic obstructive pulmonary disease | 21 [21.9] | 4 |
| Cerebrovascular accident | 8 [8.1] | 1 |
| Chronic renal disease | 6 [6.0] | 0 |
| Chronic liver disease | 5 [5.1] | 1 |
| Previous cancer | 16 [16.0] | 0 |
| Solid organ transplantation | 1 [1.0] | 0 |
| BMI [kg/m2], median [IQR] | 26.2 [6.97] | 21 |
| Ever smoked, n [%] | 38 [46.9] | 19 |
| Age at COVID-19 diagnosis [years], median [IQR] | 62.5 [23.0] | 0 |
| Age at IBD diagnosis [years], median [IQR] | 48.5 [31.0] | 0 |
| IBD duration [years], median [IQR] | 10.3 [12] | 0 |
| IBD type | 0 | |
| Ulcerative colitis, n [%] | 59 [59.0] | |
| Crohn’s disease, n [%] | 36 [36.0] | |
| IBD-unclassified, n [%] | 5 [5.0] | |
| Ulcerative colitis extent | 0 | |
| Proctitis [Montreal E1], n [%] | 13 [20.6] | |
| Left-sided colitis [Montreal E2], n [%] | 30 [47.6] | |
| Extended colitis [Montreal E3], n [%] | 20 [31.7] | |
| Crohn’s disease extent | 0 | |
| Ileal [Montreal L1], n [%] | 17 [43.6] | |
| Colonic [Montreal L2], n [%] | 10 [25.6] | |
| Ileocolonic [Montreal L3], n [%] | 12 [30.8] | |
| Upper gastrointestinal disease [Montreal L4], n [%] | 2 [5.7] | |
| Perianal disease activity, n [%] | 6 [15.8] | |
| Crohn’s disease phenotype | 6 | |
| Non-stricturing, non- penetrating [Montreal B1], n [%] | 26 [76.5] | |
| Stricturing [Montreal B2], n [%] | 5 [14.7] | |
| Penetrating [Montreal B3], n [%] | 3 [8.8] | |
| IBD activity by physician global assessment | 4 | |
| Remission, n [%] | 70 [72.9] | |
| Mild, n [%] | 16 [16.7] | |
| Moderate, n [%] | 8 [8.3] | |
| Severe, n [%] | 2 [2.1] | |
| Concomitant IBD-related medical therapy, n [%] | ||
| None | 23 [23.0] | 0 |
| Systemic corticosteroids | 22 [22.2] | 1 |
| 5-aminosalicylates | 56 [56.0] | 0 |
| Thiopurines | 24 [24.0] | 0 |
| Methotrexate | 2 [2.0] | 0 |
| Calcineurin inhibitors | 0 [0] | 0 |
| Anti-TNF | 13 [13.1] | 1 |
| Vedolizumab | 1 [1.0] | 0 |
| Ustekinumab | 1 [1.0] | 0 |
| Tofacitinib | 1 [1.0] | 0 |
n, number; IBD, inflammatory bowel disease; TNF, tumour necrosis factor; IQR, interquartile range; BMI, body mass index.